MedTrace Logo

Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic

NCT04426006 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 526

Last updated 2025-09-03

Study results available
· View outcomes & findings →

Summary

The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue. Knowing the evolution of this response over time in this population can help answer outstanding questions. The PRO-SERO-COV study is a seroprevalence study of caregivers working in the hospital sector with a follow-up at 3 months and 12 months. The objective is to evaluate and monitor at 3 and 12 months the serological immune status to an infection by the SARS-CoV-2 virus in active volunteer professionals working at the Institut Bergonié with different types of exposure: healthcare professionals and professionals in other services.

Conditions

  • Sars-CoV2
  • Serum; Disease

Interventions

OTHER

PRO-SERO-COV

At inclusion, 3 months and 12 months : * blood sample (2 x 5ml) * self-administered questionnaire

Sponsors & Collaborators

  • Institut Bergonié

    lead OTHER

Principal Investigators

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-18
Primary Completion
2021-01-26
Completion
2021-10-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04426006 on ClinicalTrials.gov